Cipla reported revenues over Rs. 7,000 crores for Q3 FY26, despite a drop in generic Revlimid sales. The One-India business grew by 10%. Respiratory grew by 11%, anti-diabetes and cardiac grew by 13% each, and urology grew by 15%. The company expects Lanreotide resupply to resume in H1 FY’27. The company anticipates re-inspection of its Indore facility anytime soon.
Financial Performance
Cipla’s Q3 FY26 revenues exceeded Rs 7,000 crores, despite facing generic Revlimid sales decline. The EBITDA margin stood at 17.7%, excluding other income. The One-India business showed robust growth at 10% year-on-year. The overall chronic mix strengthened to 62.3% YOY.
Therapy Performance
Key therapies continued to outperform the market, exhibiting robust growth. Specifically, Respiratory grew by 11%, while the anti-diabetes and cardiac segments each grew by 13%, and Urology grew by 15%.
Strategic Agreements and Acquisitions
Cipla entered into a strategic agreement with Pfizer for the exclusive marketing and distribution of four established Pfizer brands in India. They also signed a definitive agreement to acquire Inzpera Health Sciences, integrating its pediatric pharmaceutical and wellness products into Cipla’s distribution network.
Product Launches and Partnerships
The company launched Afrezza, India’s first inhaled rapid-acting insulin, and Yurpeak, a once-weekly tirzepatide therapy for obesity and type 2 diabetes, through a partnership with Eli Lilly.
Regional Performance
In North America, Cipla delivered quarterly revenue of $167 million, inclusive of a small contribution from Lenalidomide. South Africa private market achieved a strong secondary growth of 6.3%. EMEU delivered its fourth consecutive quarterly revenue above $100 million, recording a 7% YOY growth in USD terms.
Regulatory and Operational Updates
Cipla expects the re-inspection of its Indore facility soon. A U.S. FDA inspection at Pharmathen’s manufacturing facility resulted in nine 483 observations, temporarily pausing production. Lanreotide resupply is expected to resume in H1 FY’27.
Key Priorities
Cipla’s priorities include focusing on execution to sustain growth momentum in One India, enhancing commercial execution in North America, improving the private sector mix in South Africa, and driving top-line growth in EMEU.
Source: BSE
